Moreover, EAAT1 was found to be overexpressed and cause glutamate efflux in aggressive glioblastomas, which indicates selective EAAT1 inhibitors as a potential treatment option for glioma (Corbetta et al., 2019). Here, SLC1A3 is linked to central nervous system cancer.